✦ LIBER ✦

Efficacy of solanezumab in patients with mild or moderate Alzheimer's disease: Pooled analyses findings from two phase III studies

✍ Scribed by Carlson, Christopher; Sundell, Karen; Estergard, Wahiba; Raskin, Joel; Liu-Seifert, Hong; Case, Michael; Sethuraman, Gopalan; Chen, Yun-Fei; Henley, David; DeMattos, Ronald; Siemers, Eric

Book ID: 122875294
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 54 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.04.082

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of Intravenous Solan

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 50 KB

Effects of solanezumab versus placebo ad

Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials

✍ Dean, Robert; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Correlation of brain atrophy with clinic

Correlation of brain atrophy with clinical progression in mild-to-moderate Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab

✍ Novak, Gerald; Einstein, Steven; Lu, Yuan; Tudor, Iulia Cristina; Gregg, Keith; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONT

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

✍ Cummings, Jeffrey; Cho, William; Ward, Michael; Friesenhahn, Michel; Brunstein, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB

P.4.044 Long-term efficacy of donepezil

P.4.044 Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study

✍ B. Winblad; A. Wimo; A.-L. Wetterholm; A. Haglund; K. Engedal; H. Soininen; F.R. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Safety, tolerability, and preliminary ef

Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer's disease: Results from a phase 2a study

✍ Claudine Brisard; Beth Safirstein; Kevin Booth; Lisa Hua; Yves Brault; Sangeeta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB